AKT1/3 (Ab-437/434) Antibody from MYBIOSOURCE INC.

Search, find, compare suppliers for anti-AKT1/3 (Ab-437/434) antibody, protein, ELISA kits.

Edit 
Antigenic SpecificityAKT1/3 (Ab-437/434)
Clonepolyclonal
Host SpeciesRabbit
Reactive Specieshuman, mouse
Isotypen/a
Formatimmunogen affinity purified
Size0.05 mL, 0.1 mL
Concentration1.0 mg/ml
ApplicationsWestern Blot (WB)
Reviews / RatingsIf you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
DescriptionThe antibody detects endogenous levels of total AKT1/3 protein. AKT1 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificityhas been reported. AKT is responsible of the regulation of glucose uptake by mediating insulin-induced translocation of the SLC2A4/GLUT4 glucose transporter to the cell surface. Phosphorylation of PTPN1 at 'Ser-50' negatively modulates its phosphatase activity
ImmunogenImmunogen Type: Peptide Immunogen Description: Synthesized non-phosphopeptide derived from human AKT1/3 around the phosphorylation site of tyrosine 437/434 (T-R-Y(p)-F-D).
Other Names[AKT; AKT1 kinase; C-AKT; EC 2.7.11.1; kinase Akt1]
Gene, Accession #[AKT1/3], Gene ID: 207, NCBI: NP_001014431.1, UniProt: P31749
Catalog #MBS9410940
Price$200, $255
Order / More InfoAKT1/3 (Ab-437/434) Antibody from MYBIOSOURCE INC.
Product Specific Referencesn/a
MYBIOSOURCE INC.
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166

sales@mybiosource.com

http://www.MyBioSource.com

Profile of MYBIOSOURCE INC.
Return to Antibodies

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.